This article was originally posted on July 29.
Life Technologies and the University of Queensland's Institute for Molecular Bioscience said last week that they will collaborate to study pancreatic and ovarian cancer using Applied Biosystem's SOLiD sequencing platform.
Through the collaboration, IMB is scaling up its fleet of SOLiD systems to 11 from currently two instruments. ABI will also provide instrument service and support as well as bioinformatics analytical support.
For the study, which IMB will be conducting as part of the International Cancer Genome Consortium, the institute plans to sequence 500 pancreatic and ovarian tumors as well as healthy control tissues.
Earlier this year, Australia's National Health and Medical Research Council said that it will fund research into pancreatic and ovarian cancer under the ICGC with AUD$27.5 million ($22.6 million) over five years. That contribution, the NHMRC said at the time, was "instrumental" in allowing researchers to "leverage this funding to reach a total over AU$40 million."
IMB is partnering with the Garvan Institute in Sydney and a group at the Ontario Institute for Cancer Research for the work on pancreatic cancer, while IMB and the Peter McCallum Cancer Centre in Melbourne are collaborating to study ovarian cancer.
Other partners include the NSW Cancer Council, Silicon Graphics, and Applied Biosystems.
IMB is one of the earliest users of the SOLiD technology. Last year, Sean Grimmond, a group leader at the institute, published one of the first paper involving the platform, using it to profile the transcriptomes of stem cells (see In Sequence 7/15/2008).
ICGC, which currently has members from about a dozen countries and projects on eight cancer types, aims to comprehensively describe genomic, transcriptomic and epigenomic changes in 50 different tumor types and subtypes.